Welcome to the Webinar

Caring for Older Adults with Diabetes in Long Term Care

We will begin at 10:30


Use the Chat Box to tell us your name, organization and position.

May 28, 2020









Caring for Older Adults with Diabetes in Long-Term Care COVID-19 Workshop Series

May 28, 2020











The IPRO QIN-QIO Who We Are





Healthcentric
Advisors

Olarant

■ Qlarant

The IPRO QIN-QIO

- A federally funded Medicare Quality Innovation Network Quality Improvement Organization
- 12 regional CMS QIN-QIOs nationally

IPRO:


New York, New Jersey, Ohio

Healthcentric Advisors:

Maine, New Hampshire, Vermont, Massachusetts, Connecticut, Rhode Island

Qlarant:

Maryland, Delaware, District of Columbia



Working to ensure high-quality, safe healthcare for 20% of the nation's Medicare FFS beneficiaries

The IPRO QIN-QIO







Quality Innovation Network – Quality Improvement Organizations (QIN-QIOs)

- Bring together healthcare providers, stakeholders, and Medicare beneficiaries to improve the quality of healthcare for targeted health conditions
- Work toward better care, healthier people & communities, and smarter spending
- Catalyze change through a data-driven approach to improving healthcare quality
- Collaborate with providers, practitioners and stakeholders at the community level to share knowledge, spread best practices and improve care coordination
- Promote a patient-centered model of care, in which healthcare services are tailored to meet the needs of patients

Caring for Older Adults with Diabetes in Long-Term Care





Healthcentric AdvisorsOlarant

Qlarant

Our Speakers



Dr. Sarah Sy is currently a Geriatric Diabetes Fellow at Beth Israel Deaconess Medical Center and Joslin Diabetes Center in Boston, Massachusetts.

She completed her training in Internal Medicine and Geriatric Medicine at the University of British Columbia, Canada.



Dr. Darren Triller is a clinical pharmacist with 30 years of experience in medication safety and quality improvement. He has led multiple state and national efforts relating to high-risk drugs and serves as IPRO's lead for the drug safety aim for the current QIN-QIO contract.

Presentation Overview Objectives





Advisors Olarant

- Recognize the challenges of diabetes management in LTC during the COVID-19 pandemic
- Appreciate the importance of individualized glycemic goals for the patients
- Implement management strategies for patients with Type 1 and Type 2 diabetes

Challenges in Long-Term Care







- Medically complex patients
- Frequent changes in health can impact glucose levels
- Erratic intake of food and drink
- Patients are dependent on LTC staff for diabetes self-care and activities of daily living
- Patients may have behaviors that make it more difficult for glucose monitoring and adherence to treatment
- LTC facility may not have diabetes specific protocols (e.g. for hypoglycemia or hyperglycemia)
- There may be inadequate diabetes education for staff

Additional Challenges during COVID-19






Healthcentric Advisors

Qlarant

- Highest risk patients for adverse outcomes
- Limited staff and resources
- Caring for patients with COVID-19
 - Exposure and spread
 - Transitions of care
- Increased psychological stress for patients and staff









Healthcentric AdvisorsQlarant

Many Unknowns!

- Type of diabetes
- Duration
- Diabetes control/ glucose variability
- Diabetes complications

Prioritize Goals







Older adults with diabetes may have competing health priorities and geriatric syndromes

- Important to reassess the diabetes treatment plan to lower disease and treatment burden
- Provide repeated education and support

Diabetes Management Strategies in LTC





- 1. Establish individualized goals and avoid hypoglycemia
- 2. Simplify the diabetes treatment plan
 - Insulin Simplification Strategies
 - Insulin Sliding Scales
 - Glucose Monitoring
- 3. Sick Day Management

Establish Individualized Goals







■ Qlarant

Glycemic targets

Comorbidities

Functional status

Geriatric syndromes

Life expectancy

Avoidance of hypoglycemia

Guidelines American Diabetes Association 2020





Healthcentric AdvisorsQlarant

Table 12.1—Framework for considering treatment goals for glycemia,	blood pressure, and dyslipidemia in older adults with diabetes (2)
--	--

Patient characteristics/			Fasting or preprandial	
health status	Rationale	Reasonable A1C goal‡	glucose	Bedtime glucose
Healthy (few coexisting chronic illnesses, intact cognitive and functional status)	Longer remaining life expectancy	<7.5% (58 mmol/mol)	90-130 mg/dL (5.0-7.2 mmol/L)	90-150 mg/dL (5.0-8.3 mmol/L)
Complex/intermediate (multiple coexisting chronic illnesses* or 2+ instrumental ADL impairments or mild-to-moderate cognitive impairment)	Intermediate remaining life expectancy, high treatment burden, hypoglycemia vulnerability, fall	<8.0% (64 mmol/mol)	90–150 mg/dL (5.0–8.3 mmol/L)	100–180 mg/dL (5.6–10.0 mmol/L)
Very complex/poor health (LTC or end-stage chronic illnesses** or moderate-to- severe cognitive impairment or 2+ ADL dependencies)	Limited remaining life expectancy makes benefit uncertain	<8.5%† (69 mmol/mol)	100–180 mg/dL (5.6–10.0 mmol/L)	110–200 mg/dL (6.1–11.1 mmol/L)

Hypoglycemia







Increased risk of:

- Cerebrovascular events
- Arrhythmias and cardiovascular events
- Dementia
- Falls and fractures
- ED visits
- Hospitalizations
- Death







Advisors Olarant

- Ensure that the patient and healthcare team can follow the plan consistently
- Minimize the risk of hypoglycemia
- Can help reduce contact time between patient and LTC staff
- Reduce polypharmacy and consolidate medications if possible

Choosing Medications "Start low, go slow"







- 1st line for patients with Type 2 diabetes
 - Metformin provided there are no contraindications
- Additional agents
 - Depends on your LTC institution (pharmacy formulary)
 - Cost
 - Risk of hypoglycemia
 - Comorbidities
 - Cardiovascular: GLP-1RA, SGLT2 inhibitor
 - HF: SGLT2 inhibitor
 - Obesity: GLP-1RA


How can we simplify the insulin regimen if patients with Type 2 diabetes are on multiple injections per day?

Algorithm for Basal Insulin Simplification











Algorithm for Meal-time Insuling **Simplification**









19

What if oral agents are not an option?




Insulin Management Strategies





Advisors Qlarant




Insulin Management Strategies





■ Healthcentric **Advisors**

Qlarant



S


Insulin Management Strategies





■ Healthcentric Advisors

Qlarant







Advisors Olarant

Issues with Insulin Sliding Scale

- Reactive
 - Leads to wide glucose excursions
- Increases the burden for patients (more frequent fingersticks)
- Increases nursing staff resources
- AGS Beers List: Higher risk of hypoglycemia without improvement in hyperglycemia management

	BG	Insulin Sliding Scale
D1 breakfast	106	0 units
D1 lunch	276	2 units
D1 dinner	184	0 units





IPRO Qlarant

Insulin Regimen

Sliding scale is sole mode of insulin treatment

Sliding scale is being used in addition to basal and scheduled meal-time insulin

Sliding scale is being used in addition to scheduled basal

Sliding scale is being used short term due to irregular dietary intake or due to acute illness

Strategy

- Stop SSI
- Use non-insulin agents or fixed dose meal-time insulin for post-prandial hyperglycemia
- Give 50-75% of average daily sliding scale insulin as basal
- If sliding scale is being used frequently, add the average correction dose to the preceding mealtime insulin dose and stop SSI
- Use simplified correction scale
- Use non-insulin agents or fixed dose meal-time insulin
- Add 50-75% of average daily sliding scale insulin to basal
- Once health and glucose stabilize, stop SSI

Type 1 Diabetes







Patients with Type 1 Diabetes always require insulin

- Basal insulin
- Regular meal-time insulin
- A simplified correction scale can be added if blood sugars are higher than anticipated goal

E.g. If BG > 250, give 1 additional unit; if BG > 350, give 2 additional units

Strategies for Type 1 DM with wide glucose excursions

- Rule out other causes (infection, change in health status) for glucose variability
- Change insulin from bedtime to morning
 - Avoid morning lows overnight gluconeogenesis is not as prominent in older adults
- If the patient skips meal, omit the mealtime insulin
- If eating is erratic, administration of insulin can occur immediately postprandially

Glucose Monitoring







- Patients with Type 1 diabetes still require glucose checks before meals
- In patients with Type 2 diabetes, glucose monitoring can be decreased to once per day if diabetes control is stable
 - Check fasting glucose on some days; pre-lunch or pre-dinner on other days
 - · If glycemic control is optimal, less frequent testing is recommended
 - Stop checking blood sugars before bedtime

Sick Day Management





Advisors Olarant

- Encourage fluid intake to reduce risk of dehydration and falls
- More frequent glucose monitoring
- Hold metformin and SGLT2 inhibitors
- Use short-term insulin if experiencing significant hyperglycemia
- Testing for ketones in Type 1 patients
- Diabetic ketoacidosis and Hyperosmolar Hypoglycemic Syndrome are medical emergencies

For patients with COVID-19 infection:

- Tend to have increased insulin resistance
 - May require short term insulin

Utilizing Technology in the LTC Setting





- Telemedicine
 - Consultations with Diabetologists
 - Retinopathy Screening
 - Diabetic Footcare
- Continuous blood glucose monitoring

Key Takeaways





Healthcentric AdvisorsOlarant

• Qlarant

- Established individualized glycemic goals for older adults with diabetes in LTC
- Simplify the diabetes treatment plan
 - Lower disease and treatment burden
 - Avoid hypoglycemia
- Capitalize on technology to address the patients' needs



Resources





Healthcentric AdvisorsOlarant

COVID-19:

- American Diabetes Association: <u>https://professional.diabetes.org/content-page/covid-19</u>
- Joslin Diabetes Center COVID-19 Course: <u>https://www.joslin.org/covid-19-diabetes-courseles</u>
- Lancet Practical Recommendations for the management of diabetes in patients with COVID-19: https://doi.org/10.1016/S2213-8587(20)30152
- American Geriatrics Society Policy Brief: COVID-19 and Nursing Homes: https://doi.org/10.1111/jgs.16477

Diabetes care in Older Adults

- American Diabetes Association Older Adults: Standards of Medical Care in Diabetes 2020:
 - https://doi.org/10.2337/dc20-S012
- Management of Diabetes in Long-term Care and Skilled Nursing Facilities: A Position Statement of the American Diabetes Association:
 - https://doi.org/10.2337/dc15-2512
- Insulin Simplification Algorithm: https://doi.org/10.1001/jamainternmed.2016.2

Dr. Sarah Sy, MD, FRCPC 1 Joslin Place Boston, MA 02199 Sarah.sy@joslin.harvard.edu






■ Qlarant

Learn More & Stay Connected

https://qi.ipro.org/



Follow IPRO QIN-QIO



This material was prepared by the IPRO QIN-QIO, a collaboration of Healthcentric Advisors, Qlarant and IPRO, serving as the Medicare Quality Innovation Network-Quality Improvement Organization for the New England states, NY, NJ, OH, DE, MD, and the District of Columbia, under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services. The contents do not necessarily reflect CMS policy. 12SOW-IPRO-QIN-T1-AA-20-66.





- Healthcentric Advisors
- Qlarant